Prof. Rumen Stoilov (University Hospital St. Ivan Rilski, Bulgaria) presented the randomised, placebo-controlled, multicentre, phase 3 CREDO-1 trial that evaluated the efficacy and safety of olokizumab, a new humanised monoclonal antibody targeting interleukin(IL)-6 [3,4]. The trial aimed to evaluate the safety and efficacy of olokizumab 64 mg administered subcutaneously every 2 weeks and 64 mg subcutaneously every 4 weeks versus placebo in the treatment of moderate-to-severe active RA despite treatment with methotrexate. Participants (n=428) received injections of olokizumab 64 mg every 2 weeks (n=143), olokizumab 64 mg every 4 weeks (n=142), or placebo every 2 weeks (n=143) for 24 weeks. After week 24, patients could qualify for an open-label study extension. Primary endpoint of the study was American College of Rheumatology (ACR)20 response at week 12. Secondary endpoints included percentage of patients with low disease activity and improvement of physical ability. Baseline characteristics were comparable between treatment arms.
The results showed that 90.9% of patients in the 2-week dosing group, 94.4% in the 4-week dosing group, and 92.3% in the placebo group completed the study. Both regimens of olokizumab were significantly better than placebo in all primary and secondary endpoints, with 63.6% of patients in the 2-week dosing group and 70.4% of those in the 4-week dosing group achieving ACR20 at week 12 versus 25.9% of patients receiving placebo. The rates for disease activity score (DAS)28 response were 33.6%, 38.7%, and 3.5%, respectively.
Regarding the effect of treatment on quality of life (QoL), work productivity, and fatigue, the 3 groups were compared for a wide range of PROs, including change from baseline in Health Assessment Questionnaire-Disability Index (HAQ-DI); Patient Global Assessment of Disease Activity (PtGA); Patient Assessment of Arthritis Pain (Pain); Short Form 36 (SF-36) Physical (PCS) and Mental (MCS) components; European Quality of Life-Five-Dimension Questionnaire (EQ-5D); Functional Assessment of Chronic Illness Therapy-Fatigue Scale (FACIT-F); and Work Productivity Survey-Rheumatoid Arthritis (WPS-RA) [2]. PRO baseline characteristics were comparable across treatment arms: mean (SD) PtGA was 69.5 (15.5); Pain was 68.6 (17.5); HAQ-DI was 1.7 (0.5); SF-36 PCS was 32.1 (6.5); SF-36 MCS was 42.3 (10.0); EQ-5D was 40.3 (20.0); and FACIT-F was 26.8 (8.7). At week 12, treatment with olokizumab 64 mg every 2 weeks and olokizumab 64 mg every 4 weeks resulted in significant improvement in PRO measures, and these improvements were persistent up to week 24 (see Table).
Table: Patient-reported outcomes change from baseline [2]

The incidence of treatment-emergent serious adverse events was numerically higher in the olokizumab groups when compared to placebo, but no unexpected safety signals emerged [1]. The safety profile of olokizumab was consistent with what had previously been shown in phase 2 trials with this agent and with data for agents with a similar mechanism of action. At a time when interleukin-6 blockers are in short supply this work highlights the ongoing interest of interleukin-6 antagonism in rheumatoid arthritis.
- Nasonov E, et al. Abstract OP0021. EULAR E-Congress, 3-6 June 2020.
- Nasonov E, et al. THU0176. EULAR E-Congress, 3-6 June 2020.
- Genovese MC, et al. Ann Rheum Dis. 2014;73:1607-1615.
- Takeuchi T, et al. Mod Rheumatol. 2016;26:473-480.
Posted on
Previous Article
« Low DAS at 4 months predicts sustained DMARD-free remission Next Article
New nanoparticle promising future agent in RA »
« Low DAS at 4 months predicts sustained DMARD-free remission Next Article
New nanoparticle promising future agent in RA »
Table of Contents: EULAR 2020
Featured articles
COVID-19 and inflammatory rheumatic disease: some key issues
Secukinumab monotherapy as efficient as adalimumab
AxSpA real-life remission rates higher on biologics
Olokizumab significantly improves RA features and patient-reported outcomes
Rheumatoid Arthritis
New nanoparticle promising future agent in RA
Olokizumab significantly improves RA features and patient-reported outcomes
Low DAS at 4 months predicts sustained DMARD-free remission
Ankylosing Spondylitis
Reduced maintenance dose of certolizumab pegol can be used in axSpA
Worse response axSpA patients to second TNFi versus first TNFi
AxSpA real-life remission rates higher on biologics
Certolizumab pegol reduces acute anterior uveitis in axial spondyloarthritis
TNF-α inhibitors improve bone mineral density in AS patients
Psoriatic Arthritis
Ixekizumab shows sustained improvements in pain and fatigue at 3 years
Adalimumab added to methotrexate yields better results in PsA than methotrexate escalatio
Upadacitinib provides fast onset of improvement in psoriatic arthritis
Secukinumab monotherapy as efficient as adalimumab
Osteoporosis and Osteoarthritis
Higher mortality risk with tramadol versus NSAIDs for osteoarthritis patients
Hydroxychloroquine not effective in patients with hand osteoarthritis
Positive effect denosumab on fall risk
Systemic Sclerosis and Systemic Lupus Erythematosus
Anifrolumab achieves rapid and durable BICLA-response
Subclinical myocardial involvement progresses in SSc patients
Composite endpoint CRESS for primary Sjögren’s syndrome
COVID-19
COVID-19 and inflammatory rheumatic disease: some key issues
Related Articles

November 12, 2020
ACR 2020 Highlights Podcast

© 2024 Medicom Medical Publishers. All rights reserved. Terms and Conditions | Privacy Policy
HEAD OFFICE
Laarderhoogtweg 25
1101 EB Amsterdam
The Netherlands
T: +31 85 4012 560
E: publishers@medicom-publishers.com